Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).
After hours: January 17 at 7:51:34 PM EST Loading Chart for BB ...
Pre-Market: 4:36:54 a.m. EST ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback